Windtree Therapeutics has more than doubled in price over the past month — yet shorts have almost entirely stepped aside, leaving a volatile micro-cap with little structural pressure in either direction.
The price move is the headline. WINT closed at $0.0245 on April 29, up 16% on the week and 160% over the past month. That kind of run in a sub-penny-stock is driven by order flow, not fundamentals — the company carries a market cap of roughly $1 million and trades on the OTC Pink market. The gains arrive on the same day the company was expected to report full-year 2025 and Q4 2025 results, both of which were estimated rather than confirmed events per S&P Global's calendar. There is no confirmed transcript or call details on file. Two prior earnings prints in late 2025 produced sharp declines: the stock fell 12.5% the day after the November 25 release, and a further 14.6% after the November 19 print — with five-day losses of 19% and 15% respectively. That pattern is worth noting against the week's run-up.
Short positioning tells a quiet story. Short interest is negligible at around 0.12% of the free float — roughly 56,000 shares. That figure is down 35% on the week after a step-change lower on April 23, though the month-long view shows an extraordinary spike: shorts went from around 4,000 shares in early April to a peak near 92,000 before retreating. Even at the peak, the absolute level was trivial relative to float. Borrow availability is, for practical purposes, unlimited — ORTEX availability registers at the maximum ceiling — meaning any short seller faces no structural obstacle to establishing a position. Cost-to-borrow data has a staleness flag (last reading April 13 at 16.2%, down sharply from over 60% through most of March), so the current borrow rate is unclear, but the loose availability suggests borrow pressure has eased materially.
The ORTEX short score registers at 25.9 — well below the levels that signal crowded short positioning. The days-to-cover rank sits at the 99th percentile of the universe, but that reflects the stock's near-zero daily trading volume rather than meaningful short conviction. On factor scores, the short score percentile rank of 95 points to how unusual even the modest observed short interest is relative to the broader stock universe — a quirk of the extremely low float count rather than evidence of targeted bear conviction.
Peer context adds some colour. Closest correlated names ABSI and SCNI gained 28% and 31% respectively over the week, suggesting a broader micro-cap biotech bid. GLMD and DTIL both fell — down 17% and 13% — pointing to dispersion rather than a clean sector tide. WINT's 16% weekly gain puts it in the middle of a wide peer range.
The next observable catalyst is whether the earnings release materialises with any substantive disclosure. With two prior prints producing double-digit sell-offs, how the market responds to any formal results filing — and whether the recent price run holds — is the clearest thing to watch from here.
See the live data behind this article on ORTEX.
Open WINT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
